Market Cap 153.09B
Revenue (ttm) 16.75B
Net Income (ttm) 1.85B
EPS (ttm) N/A
PE Ratio 38.64
Forward PE 35.79
Profit Margin 11.07%
Debt to Equity Ratio 0.50
Volume 5,251,227
Avg Vol 7,290,246
Day's Range N/A - N/A
Shares Out 1.48B
Stochastic %K 45%
Beta 0.68
Analysts Strong Sell
Price Target $120.50

Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal sur...

Industry: Medical Devices
Sector: Healthcare
Phone: 508 683 4000
Address:
300 Boston Scientific Way, Marlborough, United States
Reanimated666
Reanimated666 Jul. 17 at 12:00 PM
$BSX Looks as if it’s going to make a gigantic shit into gap
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:52 PM
BTIG has adjusted their stance on Boston Scientific ( $BSX ), setting the rating to Buy with a target price of 93 → 97.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:43 PM
Truist Securities updates rating for Boston Scientific ( $BSX ) to Buy, target set at 73 → 79.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:40 PM
Truist Securities updates rating for Boston Scientific ( $BSX ) to Buy, target set at 79 → 86.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:31 PM
Truist Securities has updated their rating for Boston Scientific ( $BSX ) to Buy with a price target of 120.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:24 PM
Canaccord Genuity has updated their rating for Boston Scientific ( $BSX ) to Buy with a price target of 117.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:13 PM
Baird updates rating for Boston Scientific ( $BSX ) to Outperform, target set at 112 → 120.
0 · Reply
Ro_Patel
Ro_Patel Jul. 16 at 5:47 PM
Medical costs & health insurance prices keep rising: Medical services increased +0.6% from May & are +3.4% higher than a year ago. That category includes hospital services, which are +4.2% higher than a year ago & nursing home care, which is up +5.1%. Prescription drug prices inched up +0.4% from May & are +1.2% higher than last April. Over-the-counter drug prices slowed by -1% monthly & -1.7% y/y Health insurance rose +3.4% compared to June 2024 & was up +0.6% monthly $XLV - $UNH $MDT $BSX $ELV
0 · Reply
ChessGM
ChessGM Jul. 16 at 4:21 PM
$BSX Heads up alert! upcoming earnings on Wednesday, 7/23/2025 for $BSX Bullish (8.1) Financial Analysis: Boston Scientific Corporation (NYSE: BSX) is demonstrating strong growth trends, bolstered by strategic FDA approvals and expansions in its product lines, most notably the FARAPULSE Pulsed Field Ablation (PFA) System. The company's recent FDA approval to expand the labeling of the FARAPULSE system indicates enhanced treatment options for persistent atrial fibrillation, positioning Boston Scientific as a leader in the cardiovascular space. The P/E ratio for Boston Scientific currently reflects its growth expectations, standing competitively compared to its peers in the medical device sector. The company has shown robust EPS growth, with analysts projecting continued double-digit earnings growth fueled by its MedSurg and Cardiovascular segments. Revenue forecasts indicate sustained momentum, driven by strategic acquisitions and innovations in medical technology. Compared to peers like Medtronic and Johnson & Johnson, Boston Scientific is well-positioned with a diversified portfolio and growth-oriented strategies that capitalize on emerging market opportunities and advanced medical technologies. Upcoming Earnings Report: Boston Scientific is scheduled to announce its second-quarter results later this month. Analysts are optimistic, anticipating double-digit growth in earnings. The company has a strong track record of exceeding earnings expectations, bolstered by its strategic investments in high-growth areas such as MedSurg and electrophysiology. Historical performance has shown consistent revenue growth and margin improvements, which analysts expect to continue in the upcoming report. Analysts' consensus estimates reflect confidence in Boston Scientific's ability to maintain its growth trajectory, particularly with the recent FDA approval and strategic market expansions. The upcoming earnings report is likely to impact the stock positively, given the company's momentum and favorable market conditions. Sector Performance: The medical device sector, to which Boston Scientific belongs, is experiencing a dynamic period with significant innovation and strategic realignments. While the sector has faced challenges such as inventory adjustments post-COVID and competitive pressures, companies like Boston Scientific are driving growth through technological advancements and strategic acquisitions. The sector is witnessing a resurgence in M&A activities, which could further consolidate Boston Scientific's position as a leader. Despite macroeconomic headwinds, the sector is expected to benefit from demographic shifts and increased demand for advanced medical solutions. Overall, Boston Scientific is outperforming many of its peers, highlighting its resilience and strategic foresight in navigating a competitive landscape. - Funds were net sellers of $BSX during the previous reporting quarter. - Top 5 funds with large holdings in $BSX: - Canada Pension , MV: $629MM. Fund Rank: 75% - Farallon Capital Management LLC, MV: $380MM. Fund Rank: 74% www.faralloncapital.com - OrbiMed Advisors LLC, MV: $284MM. Fund Rank: 60% www.orbimed.com - Adage Capital P, MV: $261MM. Fund Rank: 74% www.adagecapital.com - Viking Global Investors LP, MV: $240MM. Fund Rank: 74% www.vikingglobal.com - Last 10 days performance: 0% - Last 30 days performance: 5% - Last 90 days performance: 11% Some of the latest news articles: - Title: Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System Publication Date: 7/15/2025 1:10:34 PM, Source: yahoo URL: https://finance.yahoo.com/news/boston-scientific-corp-bsx-secures-131034203.html?.tsrc=rss - Title: Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings? Publication Date: 7/15/2025 1:02:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/robust-medsurg-performance-fuel-boston-130200568.html?.tsrc=rss - Title: Why Boston Scientific (BSX) Outpaced the Stock Market Today Publication Date: 7/14/2025 10:00:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/why-boston-scientific-bsx-outpaced-220003692.html?.tsrc=rss - Title: Hinge Health Stock Earns Relative Strength Rating Upgrade Publication Date: 7/14/2025 5:08:31 PM, Source: yahoo URL: https://finance.yahoo.com/m/bdbb11bb-c9dd-3e92-8a9a-6c587d7ea44d/hinge-health-stock-earns.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal.
0 · Reply
jewell69
jewell69 Jul. 15 at 7:18 PM
trying to re-visit $BSX 103.55 7/15 3:15 pm edt 80 recent trades 07/14/2025 Sell Trade Details BSX BOSTON SCIENTIFIC CORP 80 $105.1324 $0.01 $8,410.58 07/11/2025 Buy Trade Details BSX BOSTON SCIENTIFIC CORP 80 $103.06 -$8,244.80
0 · Reply
Latest News on BSX
I'm Buying Dividend Aristocrats At Bargain Basement Prices

Jun 17, 2025, 8:00 AM EDT - 4 weeks ago

I'm Buying Dividend Aristocrats At Bargain Basement Prices

JNJ KO MDT PEP


What's Happening With Boston Scientific Stock?

Jun 16, 2025, 11:00 AM EDT - 4 weeks ago

What's Happening With Boston Scientific Stock?


3 Growth Stocks That Aren't the Magnificent 7

Jun 6, 2025, 2:42 PM EDT - 5 weeks ago

3 Growth Stocks That Aren't the Magnificent 7

CYBR


Boston Scientific announces results for first quarter 2025

Apr 23, 2025, 6:30 AM EDT - 3 months ago

Boston Scientific announces results for first quarter 2025


Boston Scientific announces agreement to acquire SoniVie Ltd.

Mar 3, 2025, 6:58 AM EST - 4 months ago

Boston Scientific announces agreement to acquire SoniVie Ltd.


What's Behind The 130% Rise In BSX Stock?

Feb 12, 2025, 7:00 AM EST - 5 months ago

What's Behind The 130% Rise In BSX Stock?


Top 4 Health Care Stocks You May Want To Dump In Q1

Jan 21, 2025, 6:06 AM EST - 6 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BBIO ISRG ITCI


Boston Scientific Jumps Ahead of Earnings

Jan 15, 2025, 6:10 AM EST - 6 months ago

Boston Scientific Jumps Ahead of Earnings


Reanimated666
Reanimated666 Jul. 17 at 12:00 PM
$BSX Looks as if it’s going to make a gigantic shit into gap
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:52 PM
BTIG has adjusted their stance on Boston Scientific ( $BSX ), setting the rating to Buy with a target price of 93 → 97.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:43 PM
Truist Securities updates rating for Boston Scientific ( $BSX ) to Buy, target set at 73 → 79.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:40 PM
Truist Securities updates rating for Boston Scientific ( $BSX ) to Buy, target set at 79 → 86.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:31 PM
Truist Securities has updated their rating for Boston Scientific ( $BSX ) to Buy with a price target of 120.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:24 PM
Canaccord Genuity has updated their rating for Boston Scientific ( $BSX ) to Buy with a price target of 117.
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 7:13 PM
Baird updates rating for Boston Scientific ( $BSX ) to Outperform, target set at 112 → 120.
0 · Reply
Ro_Patel
Ro_Patel Jul. 16 at 5:47 PM
Medical costs & health insurance prices keep rising: Medical services increased +0.6% from May & are +3.4% higher than a year ago. That category includes hospital services, which are +4.2% higher than a year ago & nursing home care, which is up +5.1%. Prescription drug prices inched up +0.4% from May & are +1.2% higher than last April. Over-the-counter drug prices slowed by -1% monthly & -1.7% y/y Health insurance rose +3.4% compared to June 2024 & was up +0.6% monthly $XLV - $UNH $MDT $BSX $ELV
0 · Reply
ChessGM
ChessGM Jul. 16 at 4:21 PM
$BSX Heads up alert! upcoming earnings on Wednesday, 7/23/2025 for $BSX Bullish (8.1) Financial Analysis: Boston Scientific Corporation (NYSE: BSX) is demonstrating strong growth trends, bolstered by strategic FDA approvals and expansions in its product lines, most notably the FARAPULSE Pulsed Field Ablation (PFA) System. The company's recent FDA approval to expand the labeling of the FARAPULSE system indicates enhanced treatment options for persistent atrial fibrillation, positioning Boston Scientific as a leader in the cardiovascular space. The P/E ratio for Boston Scientific currently reflects its growth expectations, standing competitively compared to its peers in the medical device sector. The company has shown robust EPS growth, with analysts projecting continued double-digit earnings growth fueled by its MedSurg and Cardiovascular segments. Revenue forecasts indicate sustained momentum, driven by strategic acquisitions and innovations in medical technology. Compared to peers like Medtronic and Johnson & Johnson, Boston Scientific is well-positioned with a diversified portfolio and growth-oriented strategies that capitalize on emerging market opportunities and advanced medical technologies. Upcoming Earnings Report: Boston Scientific is scheduled to announce its second-quarter results later this month. Analysts are optimistic, anticipating double-digit growth in earnings. The company has a strong track record of exceeding earnings expectations, bolstered by its strategic investments in high-growth areas such as MedSurg and electrophysiology. Historical performance has shown consistent revenue growth and margin improvements, which analysts expect to continue in the upcoming report. Analysts' consensus estimates reflect confidence in Boston Scientific's ability to maintain its growth trajectory, particularly with the recent FDA approval and strategic market expansions. The upcoming earnings report is likely to impact the stock positively, given the company's momentum and favorable market conditions. Sector Performance: The medical device sector, to which Boston Scientific belongs, is experiencing a dynamic period with significant innovation and strategic realignments. While the sector has faced challenges such as inventory adjustments post-COVID and competitive pressures, companies like Boston Scientific are driving growth through technological advancements and strategic acquisitions. The sector is witnessing a resurgence in M&A activities, which could further consolidate Boston Scientific's position as a leader. Despite macroeconomic headwinds, the sector is expected to benefit from demographic shifts and increased demand for advanced medical solutions. Overall, Boston Scientific is outperforming many of its peers, highlighting its resilience and strategic foresight in navigating a competitive landscape. - Funds were net sellers of $BSX during the previous reporting quarter. - Top 5 funds with large holdings in $BSX: - Canada Pension , MV: $629MM. Fund Rank: 75% - Farallon Capital Management LLC, MV: $380MM. Fund Rank: 74% www.faralloncapital.com - OrbiMed Advisors LLC, MV: $284MM. Fund Rank: 60% www.orbimed.com - Adage Capital P, MV: $261MM. Fund Rank: 74% www.adagecapital.com - Viking Global Investors LP, MV: $240MM. Fund Rank: 74% www.vikingglobal.com - Last 10 days performance: 0% - Last 30 days performance: 5% - Last 90 days performance: 11% Some of the latest news articles: - Title: Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System Publication Date: 7/15/2025 1:10:34 PM, Source: yahoo URL: https://finance.yahoo.com/news/boston-scientific-corp-bsx-secures-131034203.html?.tsrc=rss - Title: Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings? Publication Date: 7/15/2025 1:02:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/robust-medsurg-performance-fuel-boston-130200568.html?.tsrc=rss - Title: Why Boston Scientific (BSX) Outpaced the Stock Market Today Publication Date: 7/14/2025 10:00:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/why-boston-scientific-bsx-outpaced-220003692.html?.tsrc=rss - Title: Hinge Health Stock Earns Relative Strength Rating Upgrade Publication Date: 7/14/2025 5:08:31 PM, Source: yahoo URL: https://finance.yahoo.com/m/bdbb11bb-c9dd-3e92-8a9a-6c587d7ea44d/hinge-health-stock-earns.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal.
0 · Reply
jewell69
jewell69 Jul. 15 at 7:18 PM
trying to re-visit $BSX 103.55 7/15 3:15 pm edt 80 recent trades 07/14/2025 Sell Trade Details BSX BOSTON SCIENTIFIC CORP 80 $105.1324 $0.01 $8,410.58 07/11/2025 Buy Trade Details BSX BOSTON SCIENTIFIC CORP 80 $103.06 -$8,244.80
0 · Reply
maestro_of_the_markets
maestro_of_the_markets Jul. 15 at 5:51 PM
$IINN looks like institutional accumulation going on since order dropped! 🤔 think I will wait for $3-5 to skim some and leave the balance long term for the tender offer from $BSX or $GEHC let the bidding begin!
1 · Reply
ZacksResearch
ZacksResearch Jul. 15 at 1:34 PM
$BSX set for a Q2 earnings beat? 🔍 Boston Scientific boasts a +0.88% Earnings ESP and a Zacks Rank #2, suggesting a higher chance of surpassing estimates. With expected revenue growth in MedSurg and Cardiovascular, things look promising. 📈 Discover the full earnings preview here 👉 https://www.zacks.com/stock/news/2582291/will-robust-medsurg-performance-fuel-boston-scientifics-q2-earnings?cid=sm-stocktwits-2-2582291-body-1777&ADID=SYND_STOCKTWITS_TWEET_2_2582291_BODY_1777
0 · Reply
Quantumup
Quantumup Jul. 15 at 1:07 PM
BofA reit'd $PRCT Buy-$84 after Center of Medicare and Medicaid Services (CMS) released its proposed physician fee schedule (PFS) for 2026 which includes what a doctor will get paid to perform PRCT's Aquablation under its new Category I CPT code. $BSX $ISRG $SYK $MDT GEHC BofA said in its note:
0 · Reply
ZacksResearch
ZacksResearch Jul. 15 at 12:04 PM
$BSX riding MedSurg strength into Q2 earnings — but is it enough? Solid Cardiovascular growth + tailwinds from key tech acquisitions could make this quarter a standout. Full earnings setup here 👉 https://www.zacks.com/stock/news/2582291/will-robust-medsurg-performance-fuel-boston-scientifics-q2-earnings?cid=sm-stocktwits-2-2582291-teaser-1705&ADID=SYND_STOCKTWITS_TWEET_2_2582291_TEASER_1705
0 · Reply
jewell69
jewell69 Jul. 14 at 9:07 PM
Trades today 7/14/25 B $EWG 101 42.33 (cheaper than the shares I sold at 42.58 on 7/7) $RARE partial re-entry b 51 29.23 on a market on close trade Cheaper than my selling TODAY 50 at 30.15. early am S $EPHE 27.35 modest profit 470 B last week S 80 $BSX 105.13 modest profit B last week S 80 $SNDX 9.74 cost basis 9.53 last week I Don’t trust this stock; had a losing trade in it last month Trimming more India $MINDX today $FJSCX Japan grandpa buying big piece today in trust for all us cousins. Look at chart
1 · Reply
jewell69
jewell69 Jul. 14 at 6:35 PM
$BSX trades in the last 14 days S 119 103.67 6/24 B 80 103.06 7/11 S 80 105.23 7/14 2:29 pm EDT
0 · Reply
maestro_of_the_markets
maestro_of_the_markets Jul. 14 at 3:06 PM
$IINN 🥱 wake us when $BSX comes with the $500 million tender offer would yah?
0 · Reply
FeatherWeight
FeatherWeight Jul. 13 at 3:19 PM
$BSX $TKO Main 2 stocks I’ll be interested in this upcoming week. Earnings season around the corner. Smaller position size probably most reasonable move with newer trades. TKO forming a high handle, drifting down > wedging up. Pullback is below average volume, pulling back to 50-day/10-week. BSX also looks like it’ll make the turn up from 6% contraction. Price could tighten up into the $107.50 breakout level or the complete opposite. Don’t be a Rick… Buffet’s and Munger’s 3rd partner in their early days, who was in a rush to build wealth getting caught up with margin calls.
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Jul. 12 at 12:31 PM
$BSX beast knocking knocking at ath. breakout here should give another nice leg higher. or you buys dips. longterm winner. period
0 · Reply
jewell69
jewell69 Jul. 11 at 6:26 PM
$BSX hard to make money on Boston scientific 7/11 buy re-entry b 80 103.06 Previous trades S 119 103.68 6/24 B 6/5 59 102.80 B 6/3 60 102.97
0 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 4:54 PM
AI is transforming $BSX, $JNJ, and $GEHC — are these the 2025 winners? 🚀 Boston Scientific projects a 16.4% sales growth in 2025, driven by AI-powered diagnostics like HeartLogic and Rhythm AI, compared to the industry's flat growth. Johnson & Johnson's AI innovations in surgical robotics and digital analytics are set to boost its MedTech division, and GE HealthCare topped the FDA list with 80 AI-enabled device clearances. See why these stocks are positioned for AI-driven success 👉 https://www.zacks.com/stock/news/2573185/3-ai-driven-medical-device-stocks-to-watch-in-2025?cid=sm-stocktwits-2-2573185-body-1321&ADID=SYND_STOCKTWITS_TWEET_2_2573185_BODY_1321
0 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 12:38 PM
AI + healthcare = massive upside? $BSX, $JNJ and $GEHC are tapping AI to enhance device performance, diagnostics, and surgical precision heading into 2025. See why these 3 could lead the medtech surge 👉 https://www.zacks.com/stock/news/2573185/3-ai-driven-medical-device-stocks-to-watch-in-2025?cid=sm-stocktwits-0-2573185-teaser-1281&ADID=SYND_STOCKTWITS_TWEET_0_2573185_TEASER_1281
0 · Reply